{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:12:43Z","timestamp":1783098763665,"version":"3.54.6"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clnesp.2025.04.004","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T12:09:11Z","timestamp":1745928551000},"page":"206-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The efficacy of probiotics, prebiotics or synbiotics in scleroderma: A systematic review"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-1600","authenticated-orcid":false,"given":"Adam A.","family":"Wach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6643-1389","authenticated-orcid":false,"given":"Dawid","family":"Storman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wi\u0119ckowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Wojtaszek-G\u0142\u00f3wka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"\u017babicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Krupka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6689-3898","authenticated-orcid":false,"given":"Ahmad Kamal","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4889-2218","authenticated-orcid":false,"given":"Magdalena","family":"Celi\u0144ska-L\u00f6wenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1978-7264","authenticated-orcid":false,"given":"Malgorzata M.","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2025.04.004_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","article-title":"Role of the microbiota in immunity and inflammation","volume":"157","author":"Belkaid","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.clnesp.2025.04.004_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41577-022-00727-y","article-title":"The impact of the gut microbiome on extra-intestinal autoimmune diseases","volume":"23","author":"Miyauchi","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cei.13158","article-title":"The microbiome in autoimmune diseases","volume":"195","author":"De Luca","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.101473","article-title":"The microbiome in autoimmune rheumatic disease","volume":"34","author":"Konig","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/1028415X.2020.1758887","article-title":"Effects of long-term administration of multi-strain probiotic on circulating levels of BDNF, NGF, IL-6 and mental health in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial","volume":"25","author":"Rahimlou","year":"2022","journal-title":"Nutr Neurosci"},{"key":"10.1016\/j.clnesp.2025.04.004_bib6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib7","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clnesp.2025.04.004_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-017-0684-2","article-title":"Very early systemic sclerosis and pre-systemic sclerosis: definition, recognition, clinical relevance and future directions","volume":"19","author":"Bellando-Randone","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clnesp.2025.04.004_bib9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/rheumatology\/kew488","article-title":"Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis","volume":"56","author":"Bissell","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.clnesp.2025.04.004_bib10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2021.10.065","article-title":"Systemic sclerosis in adults. Part I: clinical features and pathogenesis","volume":"87","author":"Jerjen","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13075-016-1182-z","article-title":"Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease","volume":"18","author":"Andreasson","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clnesp.2025.04.004_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416154","article-title":"The microbiome in systemic sclerosis: pathophysiology and therapeutic potential","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnesp.2025.04.004_bib13","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.5152\/eurjrheum.2019.19103","article-title":"Gastrointestinal tract microbiota modifications in systemic sclerosis","volume":"7","author":"Volkmann","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11926-018-0758-9","article-title":"Update on the gastrointestinal microbiome in systemic sclerosis","volume":"20","author":"Bellocchi","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clnesp.2025.04.004_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12765","article-title":"Intestinal dysbiosis and probiotic applications in autoimmune diseases","volume":"152","author":"de Oliveira","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.clnesp.2025.04.004_bib16","first-page":"473","article-title":"Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease","volume":"7","author":"Ghouri","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib17","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/ibd.20525","article-title":"Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases","volume":"14","author":"Vanderpool","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clnesp.2025.04.004_bib18","doi-asserted-by":"crossref","first-page":"20841","DOI":"10.3390\/ijms160920841","article-title":"Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases","volume":"16","author":"Owaga","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnesp.2025.04.004_bib19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.copbio.2017.09.007","article-title":"Shared mechanisms among probiotic taxa: implications for general probiotic claims","volume":"49","author":"Sanders","year":"2018","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib22","series-title":"Introduction to clinical trials. Fundamentals of clinical trials","author":"Friedman","year":"2015"},{"key":"10.1016\/j.clnesp.2025.04.004_bib23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and Mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.clnesp.2025.04.004_bib24","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"10.1016\/j.clnesp.2025.04.004_bib25","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","year":"2011"},{"key":"10.1016\/j.clnesp.2025.04.004_bib26","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3899\/jrheum.110225","article-title":"Minimally important differences of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument","volume":"38","author":"Khanna","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3899\/jrheum.090375","article-title":"The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma","volume":"37","author":"Sekhon","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clnesp.2025.04.004_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46872","article-title":"Recommendations to improve quality of probiotic systematic reviews with meta-analyses","volume":"6","author":"McFarland","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clnesp.2025.04.004_bib30","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"Bmj"},{"key":"10.1016\/j.clnesp.2025.04.004_bib31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"key":"10.1016\/j.clnesp.2025.04.004_bib32","series-title":"Stata 18 meta-analysis reference manual","year":"2023"},{"key":"10.1016\/j.clnesp.2025.04.004_bib33","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.clnesp.2025.04.004_bib34","series-title":"Effect of probiotics in the treatment of gastrointestinal symptoms in patients with scleroderma","first-page":"5","volume":"2","author":"Enteshari-Moghaddam","year":"2016"},{"key":"10.1016\/j.clnesp.2025.04.004_bib35","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s10620-019-05830-0","article-title":"Effectiveness of saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis","volume":"65","author":"Garcia-Collinot","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clnesp.2025.04.004_bib36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2019.05.006","article-title":"A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease","volume":"49","author":"Low","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clnesp.2025.04.004_bib37","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/rheumatology\/kez160","article-title":"Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial","volume":"58","author":"Marighela","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.clnesp.2025.04.004_bib38","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.clnesp.2025.04.004_bib39","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of Rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clnesp.2025.04.004_bib40","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"Suppl 11","key":"10.1016\/j.clnesp.2025.04.004_bib41","first-page":"S486","article-title":"The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS)","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clnesp.2025.04.004_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semarthrit.2018.12.001","article-title":"The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: a systematic literature review","volume":"49","author":"Smith","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clnesp.2025.04.004_bib43","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clnesp.2024.02.025","article-title":"Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis","volume":"60","author":"Yang","year":"2024","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.clnesp.2025.04.004_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clnu.2023.11.010","article-title":"Comparative efficacy and tolerability of probiotic, prebiotic, and synbiotic formulations for adult patients with mild-moderate ulcerative colitis in an adjunctive therapy: a network meta-analysis","volume":"43","author":"Zhou","year":"2024","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnesp.2025.04.004_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10163497","article-title":"The effect of probiotics on quality of life, depression and anxiety in patients with irritable bowel syndrome: a systematic review and meta-analysis","volume":"10","author":"Le Morvan de Sequeira","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clnesp.2025.04.004_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043054","article-title":"Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis","volume":"11","author":"Goodman","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.clnesp.2025.04.004_bib47","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MCG.0000000000000814","article-title":"Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of Current evidence","volume":"51","author":"Zhong","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib48","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3899\/jrheum.110826","article-title":"Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis","volume":"39","author":"Omair","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib49","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.3748\/wjg.14.6388","article-title":"Chronic gastrointestinal symptoms and quality of life in the Korean population","volume":"14","author":"Jeong","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib50","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3122\/jabfm.18.5.393","article-title":"Managing gastroesophageal reflux disease in primary care: the patient perspective","volume":"18","author":"Liker","year":"2005","journal-title":"J Am Board Fam Pract"},{"key":"10.1016\/j.clnesp.2025.04.004_bib51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10880-010-9193-4","article-title":"Psychosocial functioning in children and adolescents with gastrointestinal complaints and disorders","volume":"17","author":"Hommel","year":"2010","journal-title":"J Clin Psychol Med Settings"},{"key":"10.1016\/j.clnesp.2025.04.004_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/nu9111247","article-title":"Probiotic, prebiotic, and brain development","volume":"9","author":"Cerdo","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.clnesp.2025.04.004_bib53","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/M18-0343","article-title":"Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review","volume":"169","author":"Bafeta","year":"2018","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.clnesp.2025.04.004_bib54","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/cid\/civ085","article-title":"Risk and safety of probiotics","volume":"60","author":"Doron","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clnesp.2025.04.004_bib55","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3899\/jrheum.141617","article-title":"Outcome of patients with systemic sclerosis in the intensive care unit","volume":"42","author":"Pene","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clnesp.2025.04.004_bib56","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/s41591-019-0626-9","article-title":"Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients","volume":"25","author":"Yelin","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.clnesp.2025.04.004_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/14740338.2014.872627","article-title":"A systematic review of the safety of probiotics","volume":"13","author":"Didari","year":"2014","journal-title":"Expet Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.clnesp.2025.04.004_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clnesp.2025.04.004_bib59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fmed.2018.00124","article-title":"Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis","volume":"5","author":"McFarland","year":"2018","journal-title":"Front Med"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457725002724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457725002724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:26:39Z","timestamp":1752765999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457725002724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":59,"alternative-id":["S2405457725002724"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2025.04.004","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of probiotics, prebiotics or synbiotics in scleroderma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2025.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}